Search company, investor...

Predict your next investment

AstraZeneca company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
astrazeneca.com

Investments

27

Funds

1

Partners & Customers

10

Service Providers

1

About AstraZeneca

AstraZeneca (LON: AZN) is a biopharmaceutical company. It focuses on the discovery, development, manufacturing, distribution and worldwide commercialization of primary care and specialty care medicines. The company was founded in 1999 and is based in Cambridge, U.K.

Headquarters Location

1 Francis Crick Avenue Cambridge Biomedical Campus

Cambridge, England, CB2 0AA,

United Kingdom

+44 (0)20 3749 5000

Want to inform investors similar to AstraZeneca about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing AstraZeneca

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find AstraZeneca in 4 Expert Collections, including Digital Health.

D

Digital Health

460 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

S

Synthetic Biology

382 items

D

Diabetes

1,903 items

B

Biopharma Tech

260 items

Latest AstraZeneca News

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CINC, ALBO, PAYA, QUMU

Jan 29, 2023

New York, New York, UNITED STATES NEW YORK, Jan. 29, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CinCor Pharma, Inc. (NASDAQ: CINC)’s sale to AstraZeneca for $26.00 per share in cash at closing, plus a non-tradable contingent value right of $10.00 per share in cash payable upon a specified regulatory submission of a baxdrostat product. If you are a CinCor shareholder, click here to learn more about your rights and options . Per the terms of the proposed transaction, Ipsen would acquire Albireo for $42.00 per share in cash plus one contingent value right per share (CVR), entitling its holder to deferred cash payments of $10.00 per CVR payable upon the U.S. Food and Drug Administration’s approval of Bylvay in the Biliary Atresia indication by December 31, 2027. If you are an Albireo shareholder, click here to learn more about your rights and options .

AstraZeneca Investments

27 Investments

AstraZeneca has made 27 investments. Their latest investment was in Doctor.One as part of their Grant on August 8, 2022.

CBI Logo

AstraZeneca Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/1/2022

Grant

Doctor.One

$0.09M

Yes

1

3/23/2022

Corporate Minority

Huma

$33M

Yes

2

11/16/2021

Series B - III

Gaoguang Pharmaceutical

$15.68M

Yes

1

9/23/2021

Corporate Minority

Subscribe to see more

Subscribe to see more

10

9/16/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/1/2022

3/23/2022

11/16/2021

9/23/2021

9/16/2020

Round

Grant

Corporate Minority

Series B - III

Corporate Minority

Series A

Company

Doctor.One

Huma

Gaoguang Pharmaceutical

Subscribe to see more

Subscribe to see more

Amount

$0.09M

$33M

$15.68M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

2

1

10

10

AstraZeneca Acquisitions

19 Acquisitions

AstraZeneca acquired 19 companies. Their latest acquisition was CinCor Pharma on January 09, 2023.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/9/2023

Series B

$99M

$193M

Acq - Pending

1

11/29/2022

Series A

$99M

$125M

Acquired

38

7/5/2022

$99M

Acquired

13

7/21/2021

Other

Subscribe to see more

$99M

$99M

Subscribe to see more

10

12/17/2015

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

1/9/2023

11/29/2022

7/5/2022

7/21/2021

12/17/2015

Investment Stage

Series B

Series A

Other

Series B

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$193M

$125M

$99M

$99M

Note

Acq - Pending

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

1

38

13

10

10

AstraZeneca Fund History

1 Fund History

AstraZeneca has 1 fund, including AstraZeneca Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

2/14/2020

AstraZeneca Fund

$229M

1

Closing Date

2/14/2020

Fund

AstraZeneca Fund

Fund Type

Status

Amount

$229M

Sources

1

AstraZeneca Partners & Customers

10 Partners and customers

AstraZeneca has 10 strategic partners and customers. AstraZeneca recently partnered with AIM ImmunoTech on January 1, 2023.

Date

Type

Business Partner

Country

News Snippet

Sources

1/17/2023

Partner

United States

2

1/11/2023

Partner

United Kingdom

AstraZeneca’s Airsupra gets US approval as new rescue treatment for asthma

The co-development partnership between AstraZeneca and Avillion LLP has recently expanded to include the BATURA study , a randomized phase IIIb decentralized trial to further assess the role of Airsupra in reducing the risk of asthma exacerbations .

3

1/5/2023

Partner

United States

Tempus, AstraZeneca Collaborate on Response Biomarker Discovery for Small Cell Lung Cancer

NEW YORK -- Tempus said Thursday that it is collaborating with AstraZeneca on a prospective clinical study to identify biomarkers of response in small cell lung cancer patients .

1

1/5/2023

Partner

United States

Subscribe to see more

Subscribe to see more

10

12/21/2022

Partner

United Arab Emirates

Subscribe to see more

Subscribe to see more

10

Date

1/17/2023

1/11/2023

1/5/2023

1/5/2023

12/21/2022

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

United States

United Kingdom

United States

United States

United Arab Emirates

News Snippet

AstraZeneca’s Airsupra gets US approval as new rescue treatment for asthma

The co-development partnership between AstraZeneca and Avillion LLP has recently expanded to include the BATURA study , a randomized phase IIIb decentralized trial to further assess the role of Airsupra in reducing the risk of asthma exacerbations .

Tempus, AstraZeneca Collaborate on Response Biomarker Discovery for Small Cell Lung Cancer

NEW YORK -- Tempus said Thursday that it is collaborating with AstraZeneca on a prospective clinical study to identify biomarkers of response in small cell lung cancer patients .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

3

1

10

10

AstraZeneca Service Providers

1 Service Provider

AstraZeneca has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acq - P2P

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

AstraZeneca Team

83 Team Members

AstraZeneca has 83 team members, including current Chief Executive Officer, Pascal Soriot.

Name

Work History

Title

Status

Pascal Soriot

Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Pascal Soriot

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare AstraZeneca to Competitors

P
Paige

Paige delivers AI-integrated digital diagnostics solutions and biomarkers for pathologists, oncologists, and the research and development community. It works with biopharma companies to create custom diagnostic solutions and drug development technologies to improve patient care. The firm's target customers include pathologists, hospital leads, and chairs as well as life sciences research and translational teams. The company was founded in 2017 and is based in New York, New York.

B
BRAVIS

BRAVIS is a software and system house. It develops high-end internet-based video conference systems.

S
Seqirus

Seqirus is an influenza vaccine company with research and production capabilities and manufacturing plants in the US, UK, Germany and Australia.

H
HAPLN Science

HAPLN Science is a drug development company that focuses on anti-aging therapies that can reverse tissue and organ degeneration. The company's products include treatments for degenerative arthritis, skin aging treatment, hair loss, and connective tissue disease. HAPLN Science was founded in 2018 and is based in Seongnam, South Korea.

Syntr Health Technologies Logo
Syntr Health Technologies

Syntr Health Technologies specializes in the micro fragmentation of adipose tissue for body contouring. The company was founded in 2016 and is based in Irvine, California.

Civica Rx Logo
Civica Rx

Civica Rx is a not-for-profit generic drug company that will help patients by addressing shortages and high prices of lifesaving generic medications.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.